Soleno Historical Income Statement
| SLNO Stock | USD 58.34 1.12 1.96% |
Historical analysis of Soleno Therapeutics income statement accounts such as Research Development of 26.4 M, Cost Of Revenue of 1.3 M, Total Operating Expenses of 43.5 M or Total Other Income Expense Net of 2.5 M can show how well Soleno Therapeutics performed in making a profits. Evaluating Soleno Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Soleno Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Soleno Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Soleno Therapeutics is a good buy for the upcoming year.
Soleno |
About Soleno Income Statement Analysis
Soleno Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Soleno Therapeutics shareholders. The income statement also shows Soleno investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Soleno Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Soleno Therapeutics. It is also known as Soleno Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Soleno Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Soleno Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.At this time, Soleno Therapeutics' Reconciled Depreciation is very stable compared to the past year. As of the 27th of November 2024, Net Interest Income is likely to grow to about 587 K, while Depreciation And Amortization is likely to drop about 1.8 M.
Soleno Therapeutics income statement Correlations
Click cells to compare fundamentals
Soleno Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Soleno Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 7.5M | 2.2M | 2.2M | 2.2M | 2.0M | 1.8M | |
| Selling General Administrative | 6.9M | 8.8M | 10.8M | 9.8M | 13.5M | 7.4M | |
| Other Operating Expenses | 23.2M | 31.9M | 32.3M | 25.1M | 41.4M | 43.5M | |
| Operating Income | (23.5M) | (36.3M) | (31.5M) | (24.4M) | (41.4M) | (39.3M) | |
| Ebit | (23.5M) | (32.2M) | (30.9M) | (24.1M) | (39.0M) | (37.0M) | |
| Research Development | 16.3M | 23.2M | 21.5M | 15.3M | 25.2M | 26.4M | |
| Ebitda | (15.9M) | (30.0M) | (28.7M) | (21.9M) | (37.0M) | (35.2M) | |
| Cost Of Revenue | 2.3M | 2.2M | 2.2M | 2.2M | 2.0M | 1.3M | |
| Total Operating Expenses | 23.2M | 31.9M | 32.3M | 25.1M | 41.4M | 43.5M | |
| Income Before Tax | (30.8M) | (24.6M) | (30.9M) | (24.1M) | (39.0M) | (37.0M) | |
| Total Other Income Expense Net | (7.3M) | 11.7M | 618K | 330K | 2.4M | 2.5M | |
| Net Income | (35.9M) | (15.4M) | (29.6M) | (20.3M) | (39.0M) | (37.0M) | |
| Income Tax Expense | 5.1M | (9.3M) | (1.3M) | (3.7M) | 2.7M | 2.8M | |
| Gross Profit | (2.3M) | (2.2M) | (2.2M) | (2.2M) | (2.0M) | (2.1M) | |
| Net Income From Continuing Ops | (30.8M) | (24.6M) | (30.9M) | (24.1M) | (33.2M) | (34.8M) | |
| Non Operating Income Net Other | (1.6M) | 2.5M | (7.3M) | 11.7M | 13.4M | 14.1M | |
| Net Income Applicable To Common Shares | (30.8M) | (24.6M) | (30.9M) | (24.1M) | (21.7M) | (22.7M) | |
| Reconciled Depreciation | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.1M | |
| Net Interest Income | 154K | 13K | 110K | 300K | 559K | 587.0K |
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Soleno Stock
| 0.83 | MTEM | Molecular Templates | PairCorr |
| 0.71 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.71 | AGL | agilon health | PairCorr |
| 0.69 | VALN | Valneva SE ADR | PairCorr |
| 0.67 | NKTX | Nkarta Inc | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.